About: Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen
Creator	Zhang, Xia Jiang, Xin Li, Cui Zhang, Tong Zhang, Zhi-Jie Chu, Nai-Hui Deng, Qun-Yi Fu, Ji-You Guo, Xiao-Yan Lu, Zhen-Hui Qiu, Lei Shao, Chang-Rong Wang, Zhao-Long Wu, Ding-Zhong Xiao, He-Ping Yan, Xiao-Feng Zhang, Hui-Yong Zhang, Shao-Yan Zheng, Pei-Yong Zheng, Yue-Juan
Source	PMC
abstract	BACKGROUND: China is the second highest pulmonary tuberculosis (PTB) burden country worldwide. However, retreatment of PTB has often developed resistance to at least one of the four first-line anti-TB drugs. The cure rate (approximately 50.0–73.3%) and management of retreatment of PTB in China needs to be improved. Qinbudan decoction has been widely used to treat PTB in China since the 1960s. Previously clinical studies have shown that the Qinbudan tablet (QBDT) promoted sputum-culture negative conversion and lesion absorption. However, powerful evidence from a randomized controlled clinical trial is lacking. Therefore, the aim of this study was to compare the efficacy and safety of QBDT as an adjunct therapy for retreatment of PTB. METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled clinical trial in China. People diagnosed with PTB were enrolled who received previous anti-TB treatment from April 2011 to March 2013. The treatment group received an anti-TB regimen and QBDT, and the control group was administered an anti-TB regimen plus placebo. Anti-TB treatment options included isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin for 2 months (2HRZES), followed by isoniazid, rifampicin, ethambutol for 6 months (6HRE), daily for 8 months. Primary outcome was sputum-culture conversion using the MGIT 960 liquid medium method. Secondary outcomes included lung lesion absorption and cavity closure. Adverse events and reactions were observed after treatment. A structured questionnaire was used to record demographic information and clinical symptoms of all subjects. Data analysis was performed by SPSS 25.0 software in the full analysis set (FAS) population. RESULTS: One hundred eighty-one cases of retreatment PTB were randomly divided into two groups: the placebo group (88 cases) and the QBDT group (93 cases). A total of 166 patients completed the trial and 15 patients lost to follow-up. The culture conversion rate of the QBDT group and placebo group did not show a noticeable improvement by using the covariate sites to correct the rate differences (79.6% vs 69.3%; rate difference = 0.10, 95% confidence interval (CI): - 0.02–0.23; F = 2.48, P = 0.12) after treatment. A significant 16.6% increase in lesion absorption was observed in the QBDT group when compared with the placebo group (67.7% vs 51.1%; rate difference = 0.17, 95% CI: 0.02–0.31; χ(2) = 5.56, P = 0.02). The intervention and placebo group did not differ in terms of cavity closure (25.5% vs 21.1%; rate difference = 0.04, 95% CI: - 0.21–0.12; χ(2) = 0.27, P = 0.60). Two patients who received chemotherapy and combined QBDT reported pruritus/nausea and vomiting. CONCLUSIONS: No significant improvement in culture conversion was observed for retreatment PTB with traditional Chinese medicine plus standard anti-TB regimen. However, QBDT as an adjunct therapy significantly promoted lesion absorption, thereby reducing lung injury due to Mycobacterium tuberculosis infection. TRIAL REGISTRATION: This trial is registered at ClinicalTrials.gov, NCT02313610.
has issue date	2020-05-07(xsd:dateTime)
bibo:doi	10.1186/s40249-020-00660-z
bibo:pmid	32381098
has license	cc-by
sha1sum (hex)	82b7908aa1ec00c63092bdc09b751375603ddb50
schema:url	https://doi.org/10.1186/s40249-020-00660-z
resource representing a document's title	Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen
has PubMed Central identifier	PMC7203794
has PubMed identifier	32381098
schema:publication	Infect Dis Poverty
resource representing a document's body	covid:82b7908aa1ec00c63092bdc09b751375603ddb50#body_text
is schema:about of	named entity 'pulmonary tuberculosis' named entity 'lesion' named entity 'resistance' named entity 'PTB' named entity 'traditional Chinese medicine' named entity 'pulmonary tuberculosis' named entity 'tablet' named entity 'RESISTANCE TO' named entity 'MANAGEMENT' named entity 'TREAT' named entity 'DECOCTION' named entity 'RANDOMIZED CONTROLLED CLINICAL TRIAL' named entity 'ONE OF' named entity 'clinical trial' named entity 'management' named entity 'PTB' named entity 'compare' named entity 'clinical studies' named entity 'randomized controlled clinical trial' named entity 'pulmonary tuberculosis' named entity 'anti-tuberculosis' named entity 'traditional Chinese medicine' named entity 'meta-analysis' named entity 'sputum' named entity 'Danshen' named entity 'p-aminosalicylic acid' named entity 'first-line' named entity 'adverse drug reactions' named entity 'randomization' named entity 'TCM' named entity 'WHO' named entity 'multidrug-resistant TB' named entity 'sputum' named entity 'lesion' named entity 'interquartile range' named entity 'first-line' named entity 'cavitation' named entity 'culture conversion' named entity 'placebo group' named entity 'TCM' named entity 'lactation' named entity 'inflammatory cell' named entity 'Scutellaria baicalensis' named entity 'adverse reaction' named entity 'culture conversion' named entity 'protionamide' named entity 'pruritus' named entity 'culture conversion' named entity 'antibacterial activity' named entity 'standard deviation' named entity 'sputum' named entity 'placebo' named entity '5.8' named entity 'TB treatment' named entity 'adjunct therapy' named entity 'decoction' named entity 'Shanghai' named entity 'placebo group' named entity 'ribosomal protein' named entity 'nontuberculous mycobacteria' named entity 'clinical laboratory' named entity 'Wannan Medical College'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software